- Home
- MYGN vs APPS Comparison
MYGN vs APPS Comparison
Compare MYGN & APPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- APPS
- Stock Information
- Founded
- MYGN 1991
- APPS N/A
- Country
- MYGN United States
- APPS United States
- Employees
- MYGN N/A
- APPS N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- APPS Multi-Sector Companies
- Sector
- MYGN Health Care
- APPS Miscellaneous
- Exchange
- MYGN Nasdaq
- APPS Nasdaq
- Market Cap
- MYGN 642.0M
- APPS 562.7M
- IPO Year
- MYGN 1995
- APPS N/A
- Fundamental
- Price
- MYGN $7.40
- APPS $5.19
- Analyst Decision
- MYGN Hold
- APPS Buy
- Analyst Count
- MYGN 13
- APPS 3
- Target Price
- MYGN $13.50
- APPS $4.83
- AVG Volume (30 Days)
- MYGN 1.3M
- APPS 2.8M
- Earning Date
- MYGN 11-06-2025
- APPS 11-05-2025
- Dividend Yield
- MYGN N/A
- APPS N/A
- EPS Growth
- MYGN N/A
- APPS N/A
- EPS
- MYGN N/A
- APPS N/A
- Revenue
- MYGN $832,900,000.00
- APPS $503,443,000.00
- Revenue This Year
- MYGN $0.17
- APPS $10.64
- Revenue Next Year
- MYGN $6.19
- APPS $11.24
- P/E Ratio
- MYGN N/A
- APPS N/A
- Revenue Growth
- MYGN 3.83
- APPS N/A
- 52 Week Low
- MYGN $3.76
- APPS $1.18
- 52 Week High
- MYGN $29.30
- APPS $7.77
- Technical
- Relative Strength Index (RSI)
- MYGN 66.01
- APPS 63.21
- Support Level
- MYGN $7.13
- APPS $4.26
- Resistance Level
- MYGN $7.80
- APPS $4.62
- Average True Range (ATR)
- MYGN 0.44
- APPS 0.30
- MACD
- MYGN 0.04
- APPS 0.15
- Stochastic Oscillator
- MYGN 78.61
- APPS 80.30
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.